Radiolabelled peptides and low molecular weight proteins in metabolic diseases

C. Aprile

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

During the last decade there has been a tremendous effort to developed labelled peptides for diagnosis and therapy. The main goal has been to develop tumor imaging/therapeutic agents, as well as peptides directed to the study of thrombosis and infection. Relatively few efforts have been made to develop peptides directed to the study of metabolic diseases. Ideally, a peptide suitable for the study of metabolism should be constructed keeping in mind the following characteristics: a) preserved affinity constant, b) preserved or improved specificity for its binding site, c) increased biological half-life in comparison with the parent peptide, d) labelling with a γ or positron emitter whose physical half-life fits with the biological half-life, e) strong binding of the nuclide to the molecule so that it cannot be released after internalization. In this paper some of the peptides or low molecular weight proteins along with some analogues which have been employed in experimental studies and in humans are reviewed, with major emphasis on amyloid seekers, insulin and leptin. Many of these radiopharmaceuticals have been labelled with iodine isotopes, however their in vivo application suffer of severe limitrations due to rapid release of iodine after internalization. On the other hand, new perspectives are opened by new radiofluorination techniques, which offer the unique advantage to quantify organ uptake and kinetics, parameters which are of paramount importance in metabolic studies.

Original languageEnglish
Pages (from-to)321-336
Number of pages16
JournalQuarterly Journal of Nuclear Medicine
Volume47
Issue number4
Publication statusPublished - Dec 2003

Fingerprint

Metabolic Diseases
Molecular Weight
Peptides
Half-Life
Proteins
Iodine Isotopes
Radiopharmaceuticals
Leptin
Amyloid
Iodine
Thrombosis
Binding Sites
Electrons
Insulin
Therapeutics
Infection
Neoplasms

Keywords

  • Amyloid
  • Aprotinin
  • Beta 2-microglobulin
  • C-peptide
  • Insulin
  • Leptin
  • Metabolism
  • Peptides
  • Radioisotopes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radiolabelled peptides and low molecular weight proteins in metabolic diseases. / Aprile, C.

In: Quarterly Journal of Nuclear Medicine, Vol. 47, No. 4, 12.2003, p. 321-336.

Research output: Contribution to journalArticle

@article{751c7bfbb021453b8af54dd41de2145a,
title = "Radiolabelled peptides and low molecular weight proteins in metabolic diseases",
abstract = "During the last decade there has been a tremendous effort to developed labelled peptides for diagnosis and therapy. The main goal has been to develop tumor imaging/therapeutic agents, as well as peptides directed to the study of thrombosis and infection. Relatively few efforts have been made to develop peptides directed to the study of metabolic diseases. Ideally, a peptide suitable for the study of metabolism should be constructed keeping in mind the following characteristics: a) preserved affinity constant, b) preserved or improved specificity for its binding site, c) increased biological half-life in comparison with the parent peptide, d) labelling with a γ or positron emitter whose physical half-life fits with the biological half-life, e) strong binding of the nuclide to the molecule so that it cannot be released after internalization. In this paper some of the peptides or low molecular weight proteins along with some analogues which have been employed in experimental studies and in humans are reviewed, with major emphasis on amyloid seekers, insulin and leptin. Many of these radiopharmaceuticals have been labelled with iodine isotopes, however their in vivo application suffer of severe limitrations due to rapid release of iodine after internalization. On the other hand, new perspectives are opened by new radiofluorination techniques, which offer the unique advantage to quantify organ uptake and kinetics, parameters which are of paramount importance in metabolic studies.",
keywords = "Amyloid, Aprotinin, Beta 2-microglobulin, C-peptide, Insulin, Leptin, Metabolism, Peptides, Radioisotopes",
author = "C. Aprile",
year = "2003",
month = "12",
language = "English",
volume = "47",
pages = "321--336",
journal = "Quarterly Journal of Nuclear Medicine",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "4",

}

TY - JOUR

T1 - Radiolabelled peptides and low molecular weight proteins in metabolic diseases

AU - Aprile, C.

PY - 2003/12

Y1 - 2003/12

N2 - During the last decade there has been a tremendous effort to developed labelled peptides for diagnosis and therapy. The main goal has been to develop tumor imaging/therapeutic agents, as well as peptides directed to the study of thrombosis and infection. Relatively few efforts have been made to develop peptides directed to the study of metabolic diseases. Ideally, a peptide suitable for the study of metabolism should be constructed keeping in mind the following characteristics: a) preserved affinity constant, b) preserved or improved specificity for its binding site, c) increased biological half-life in comparison with the parent peptide, d) labelling with a γ or positron emitter whose physical half-life fits with the biological half-life, e) strong binding of the nuclide to the molecule so that it cannot be released after internalization. In this paper some of the peptides or low molecular weight proteins along with some analogues which have been employed in experimental studies and in humans are reviewed, with major emphasis on amyloid seekers, insulin and leptin. Many of these radiopharmaceuticals have been labelled with iodine isotopes, however their in vivo application suffer of severe limitrations due to rapid release of iodine after internalization. On the other hand, new perspectives are opened by new radiofluorination techniques, which offer the unique advantage to quantify organ uptake and kinetics, parameters which are of paramount importance in metabolic studies.

AB - During the last decade there has been a tremendous effort to developed labelled peptides for diagnosis and therapy. The main goal has been to develop tumor imaging/therapeutic agents, as well as peptides directed to the study of thrombosis and infection. Relatively few efforts have been made to develop peptides directed to the study of metabolic diseases. Ideally, a peptide suitable for the study of metabolism should be constructed keeping in mind the following characteristics: a) preserved affinity constant, b) preserved or improved specificity for its binding site, c) increased biological half-life in comparison with the parent peptide, d) labelling with a γ or positron emitter whose physical half-life fits with the biological half-life, e) strong binding of the nuclide to the molecule so that it cannot be released after internalization. In this paper some of the peptides or low molecular weight proteins along with some analogues which have been employed in experimental studies and in humans are reviewed, with major emphasis on amyloid seekers, insulin and leptin. Many of these radiopharmaceuticals have been labelled with iodine isotopes, however their in vivo application suffer of severe limitrations due to rapid release of iodine after internalization. On the other hand, new perspectives are opened by new radiofluorination techniques, which offer the unique advantage to quantify organ uptake and kinetics, parameters which are of paramount importance in metabolic studies.

KW - Amyloid

KW - Aprotinin

KW - Beta 2-microglobulin

KW - C-peptide

KW - Insulin

KW - Leptin

KW - Metabolism

KW - Peptides

KW - Radioisotopes

UR - http://www.scopus.com/inward/record.url?scp=1842526464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842526464&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 321

EP - 336

JO - Quarterly Journal of Nuclear Medicine

JF - Quarterly Journal of Nuclear Medicine

SN - 1124-3937

IS - 4

ER -